Skip to main content
Top
Published in: Tumor Biology 6/2014

01-06-2014 | Research Article

RETRACTED ARTICLE: Relationship between VEGF protein expression and lymph node metastasis in papillary thyroid carcinoma among Asians: a meta-analysis

Authors: De-Feng Chang, Zhong-Qing Xu, Bin Sun

Published in: Tumor Biology | Issue 6/2014

Login to get access

Abstract

We carried out the current meta-analysis of relevant cohort studies in an attempt to investigate the relationships between vascular endothelial growth factor (VEGF) protein expression and lymph node (LN) metastasis in papillary thyroid carcinoma (PTC) among Asians. A range of electronic databases were searched, including Web of Science (1945 ∼ 2013), the Cochrane Library Database (Issue 12, 2013), MEDLINE (1966 ∼ 2013), EMBASE (1980 ∼ 2013), CINAHL (1982 ∼ 2013), and Chinese Biomedical Database (CBM) (1982 ∼ 2013) with cross-referencing without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratio (OR) with their 95 % confidence interval (95 %CI) was calculated. Twelve clinical cohort studies with a total of 1,045 PTC patients were included in our meta-analysis, The results of our meta-analysis revealed that patients with VEGF-positive tumors had a 3.02-fold higher risk of LN metastasis than that of patients with VEGF-negative tumors (OR = 3.02, 95 %CI = 2.05 ∼ 4.43, P < 0.001). Furthermore, subgroup analysis by country suggested that VEGF-positive expression was associated with an increased risk of LN metastasis in PTC patients among Chinese populations (OR = 3.33, 95 %CI = 2.30 ∼ 4.83, P < 0.001), but not among Korean, Turkish, and Japanese populations (all P > 0.05). Our findings support the view that VEGF protein expression may be correlated with LN metastasis in PTC patients, especially among Chinese populations.
Literature
2.
go back to reference Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683–9.CrossRefPubMed Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683–9.CrossRefPubMed
3.
go back to reference Lukas J, Drabek J, Lukas D, Dusek L, Gatek J. The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(3):266–75.PubMed Lukas J, Drabek J, Lukas D, Dusek L, Gatek J. The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(3):266–75.PubMed
4.
go back to reference Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W, et al. In-depth characterization of the microrna transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(8):E1401–9.CrossRefPubMed Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W, et al. In-depth characterization of the microrna transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(8):E1401–9.CrossRefPubMed
5.
go back to reference Liao S, Song W, Liu Y, Deng S, Liang Y, Tang Z, et al. Familial multinodular goiter syndrome with papillary thyroid carcinomas: mutational analysis of the associated genes in 5 cases from 1 Chinese family. BMC Endocr Disord. 2013;13(1):48.PubMedCentralCrossRefPubMed Liao S, Song W, Liu Y, Deng S, Liang Y, Tang Z, et al. Familial multinodular goiter syndrome with papillary thyroid carcinomas: mutational analysis of the associated genes in 5 cases from 1 Chinese family. BMC Endocr Disord. 2013;13(1):48.PubMedCentralCrossRefPubMed
6.
go back to reference Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–7.CrossRefPubMed Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–7.CrossRefPubMed
7.
go back to reference Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Horm (Athens). 2010;9(2):103–8.CrossRef Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Horm (Athens). 2010;9(2):103–8.CrossRef
8.
go back to reference Kabat GC, Kim MY, Wactawski-Wende J, Lane D, Wassertheil-Smoller S, Rohan TE. Menstrual and reproductive factors, exogenous hormone use, and risk of thyroid carcinoma in postmenopausal women. Cancer Causes Control. 2012;23(12):2031–40.CrossRefPubMed Kabat GC, Kim MY, Wactawski-Wende J, Lane D, Wassertheil-Smoller S, Rohan TE. Menstrual and reproductive factors, exogenous hormone use, and risk of thyroid carcinoma in postmenopausal women. Cancer Causes Control. 2012;23(12):2031–40.CrossRefPubMed
9.
go back to reference Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007;88(4):271–7.PubMedCentralCrossRefPubMed Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007;88(4):271–7.PubMedCentralCrossRefPubMed
10.
go back to reference Erdem H, Gundogdu C, Sipal S. Correlation of E-cadherin, VEGF, Cox-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol. 2011;90(3):312–7.CrossRefPubMed Erdem H, Gundogdu C, Sipal S. Correlation of E-cadherin, VEGF, Cox-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol. 2011;90(3):312–7.CrossRefPubMed
11.
go back to reference Yasuoka H, Nakamura Y, Zuo H, Tang W, Takamura Y, Miyauchi A, et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol. 2005;18(8):1127–33.CrossRefPubMed Yasuoka H, Nakamura Y, Zuo H, Tang W, Takamura Y, Miyauchi A, et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol. 2005;18(8):1127–33.CrossRefPubMed
12.
go back to reference Tian X, Cong M, Zhou W, Zhu J, Liu Q. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res. 2008;36(4):699–703.CrossRefPubMed Tian X, Cong M, Zhou W, Zhu J, Liu Q. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res. 2008;36(4):699–703.CrossRefPubMed
14.
go back to reference Poh CK, Shi Z, Lim TY, Neoh KG, Wang W. The effect of VEGF functionalization of titanium on endothelial cells in vitro. Biomaterials. 2010;31(7):1578–85.CrossRefPubMed Poh CK, Shi Z, Lim TY, Neoh KG, Wang W. The effect of VEGF functionalization of titanium on endothelial cells in vitro. Biomaterials. 2010;31(7):1578–85.CrossRefPubMed
15.
go back to reference Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120(1):106–14.CrossRefPubMed Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120(1):106–14.CrossRefPubMed
16.
go back to reference Doi K, Noiri E, Fujita T. Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol. 2010;8(1):122–8.CrossRefPubMed Doi K, Noiri E, Fujita T. Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol. 2010;8(1):122–8.CrossRefPubMed
17.
go back to reference Hsueh C, Lin JD, Wu IC, Chao TC, Yu JS, Liou MJ, et al. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. J Surg Oncol. 2011;103(5):395–9.CrossRefPubMed Hsueh C, Lin JD, Wu IC, Chao TC, Yu JS, Liou MJ, et al. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. J Surg Oncol. 2011;103(5):395–9.CrossRefPubMed
18.
go back to reference Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. Vegf and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011;17(7):347–62.CrossRefPubMed Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. Vegf and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011;17(7):347–62.CrossRefPubMed
19.
go back to reference Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2010;21(1):21–6.CrossRefPubMed Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2010;21(1):21–6.CrossRefPubMed
20.
go back to reference Salajegheh A, Pakneshan S, Rahman A, Dolan-Evans E, Zhang S, Kwong E, et al. Co-regulatory potential of vascular endothelial growth factor-a and vascular endothelial growth factor-c in thyroid carcinoma. Hum Pathol. 2013;44(10):2204–12.CrossRefPubMed Salajegheh A, Pakneshan S, Rahman A, Dolan-Evans E, Zhang S, Kwong E, et al. Co-regulatory potential of vascular endothelial growth factor-a and vascular endothelial growth factor-c in thyroid carcinoma. Hum Pathol. 2013;44(10):2204–12.CrossRefPubMed
21.
go back to reference Kamat A, Rajoria S, George A, Suriano R, Shanmugam A, Megwalu U, et al. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways. Arch Otolaryngol Head Neck Surg. 2011;137(11):1146–53.CrossRefPubMed Kamat A, Rajoria S, George A, Suriano R, Shanmugam A, Megwalu U, et al. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways. Arch Otolaryngol Head Neck Surg. 2011;137(11):1146–53.CrossRefPubMed
22.
go back to reference Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, et al. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation. Thyroid. 2011;21(4):391–9.CrossRefPubMed Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, et al. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation. Thyroid. 2011;21(4):391–9.CrossRefPubMed
23.
go back to reference de Araujo-Filho VJ, Alves VA, de Castro IV, Lourenco SV, Cernea CR, Brandao LG, et al. Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid. 2009;19(11):1233–7.CrossRefPubMed de Araujo-Filho VJ, Alves VA, de Castro IV, Lourenco SV, Cernea CR, Brandao LG, et al. Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid. 2009;19(11):1233–7.CrossRefPubMed
24.
go back to reference Yu XM, Lo CY, Lam AK, Lang BH, Leung P, Luk JM. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery. 2008;144(6):934–40. discussion 40-1.CrossRefPubMed Yu XM, Lo CY, Lam AK, Lang BH, Leung P, Luk JM. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery. 2008;144(6):934–40. discussion 40-1.CrossRefPubMed
25.
go back to reference Kim BH, Lee CH, Kim SJ, Jeon YK, Kim SS, Kim YK, et al. Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging (18)F-FDG PET-CT examination in patients with underlying malignancy. Thyroid. 2013;23(11):1431–6.PubMedCentralCrossRefPubMed Kim BH, Lee CH, Kim SJ, Jeon YK, Kim SS, Kim YK, et al. Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging (18)F-FDG PET-CT examination in patients with underlying malignancy. Thyroid. 2013;23(11):1431–6.PubMedCentralCrossRefPubMed
26.
go back to reference Li J, Teng L, Jiang H. Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma. Asia Pac J Clin Oncol. 2013;40(5):455–8. Li J, Teng L, Jiang H. Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma. Asia Pac J Clin Oncol. 2013;40(5):455–8.
27.
go back to reference Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
28.
go back to reference Zintzaras E, Ioannidis JP. Hegesma: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMed Zintzaras E, Ioannidis JP. Hegesma: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMed
29.
go back to reference Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMed Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMed
30.
go back to reference Miao AL, Wan MZ, Cheng L. Expression of Cox-2 and VEGF-C in papillary thyroid carcinoma and their relationship to cervical lymph metastases. J Clin Otorhinolaryngol Head Neck Surg. 2009;23(19):881–3. Miao AL, Wan MZ, Cheng L. Expression of Cox-2 and VEGF-C in papillary thyroid carcinoma and their relationship to cervical lymph metastases. J Clin Otorhinolaryngol Head Neck Surg. 2009;23(19):881–3.
31.
go back to reference Lee SH, Lee SJ, Jin SM, Lee NH, Kim DH, Chae SW, et al. Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer. Clin Exp Otorhinolaryngol. 2012;5(3):150–5.PubMedCentralCrossRefPubMed Lee SH, Lee SJ, Jin SM, Lee NH, Kim DH, Chae SW, et al. Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer. Clin Exp Otorhinolaryngol. 2012;5(3):150–5.PubMedCentralCrossRefPubMed
32.
go back to reference Jiang HG, Gao M, Tang WP, Li FH, Cai QZ. Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma. Chin J Cancer. 2005;24(9):1136–9. Jiang HG, Gao M, Tang WP, Li FH, Cai QZ. Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma. Chin J Cancer. 2005;24(9):1136–9.
33.
go back to reference Luo HJ, Li JP, Yang TF, Wang JD. Expression and significance of VEGF-C and VEGF-D in differentiated thyroid carcinoma. J Clin Otorhinolaryngol Head Neck Surg. 2009;12:531–4. Luo HJ, Li JP, Yang TF, Wang JD. Expression and significance of VEGF-C and VEGF-D in differentiated thyroid carcinoma. J Clin Otorhinolaryngol Head Neck Surg. 2009;12:531–4.
34.
go back to reference Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM. Increased expression of vascular endothelial growth factor c in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res. 2005;11(22):8063–9.CrossRefPubMed Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM. Increased expression of vascular endothelial growth factor c in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res. 2005;11(22):8063–9.CrossRefPubMed
35.
go back to reference Wang T, Jiang CX, Li Y, Liu X. Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid. Chin J Pathol. 2009;38(12):824–8. Wang T, Jiang CX, Li Y, Liu X. Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid. Chin J Pathol. 2009;38(12):824–8.
36.
go back to reference Wang YQ, Hua QQ. Clinical significance of HIF-1 alpha, VEGF and VEGF-C expression in papillary thyroid carcinoma. J Clin Otorhinolaryngol Head Neck Surg. 2007;21(5):204–6,8. Wang YQ, Hua QQ. Clinical significance of HIF-1 alpha, VEGF and VEGF-C expression in papillary thyroid carcinoma. J Clin Otorhinolaryngol Head Neck Surg. 2007;21(5):204–6,8.
37.
go back to reference Tanaka K, Kurebayashi J, Sonoo H, Otsuki T, Yamamoto Y, Ohkubo S, et al. Expression of vascular endothelial growth factor family messenger rna in diseased thyroid tissues. Surg Today. 2002;32(9):761–8.CrossRefPubMed Tanaka K, Kurebayashi J, Sonoo H, Otsuki T, Yamamoto Y, Ohkubo S, et al. Expression of vascular endothelial growth factor family messenger rna in diseased thyroid tissues. Surg Today. 2002;32(9):761–8.CrossRefPubMed
38.
go back to reference Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor c promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61(5):1786–90.PubMed Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor c promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61(5):1786–90.PubMed
39.
go back to reference Freeman R, Girsh J, Jou AF, Ho JA, Hug T, Dernedde J, et al. Optical aptasensors for the analysis of the vascular endothelial growth factor (VEGF). Anal Chem. 2012;84(14):6192–8.CrossRefPubMed Freeman R, Girsh J, Jou AF, Ho JA, Hug T, Dernedde J, et al. Optical aptasensors for the analysis of the vascular endothelial growth factor (VEGF). Anal Chem. 2012;84(14):6192–8.CrossRefPubMed
40.
go back to reference Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–9.PubMedCentralCrossRefPubMed Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–9.PubMedCentralCrossRefPubMed
41.
go back to reference Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A. 2009;106(32):13505–10.PubMedCentralCrossRefPubMed Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A. 2009;106(32):13505–10.PubMedCentralCrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Relationship between VEGF protein expression and lymph node metastasis in papillary thyroid carcinoma among Asians: a meta-analysis
Authors
De-Feng Chang
Zhong-Qing Xu
Bin Sun
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1725-3

Other articles of this Issue 6/2014

Tumor Biology 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine